louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04780256: Endoscopic Resection of Gastrointestinal Neoplasms
Official title: Retrospective Study of Efficacy and Safety of the Endoscopic Removal of Cancerous and Precancerous Lesions of the Upper and Lower Digestive Tract
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Endoscopic Mucosal Resection
Endoscopic Submucosal Dissection
Gastric Neoplasm
Colonic Neoplasms
Esophageal Neoplasms
Duodenal Neoplasms
Keywords: Endoscopic mucosal resection (EMR)
Endoscopic submucosal dissection (ESD)
Endoscopic full thickness resection (EFTR)
Colorectal ESD
Colorectal EMR
Lead sponsor: Azienda USL Reggio Emilia - IRCCS
Sponsor class: OTHER_GOV
First posted: 2021-03-03
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients\> 18 years of age who have undergone endoscopic resection of cancerous or pre-cancerous lesions of the digestive tract will be included in the study

Brief summary: The study aims to retrospectively investigate the endoscopic resection procedures of cancerous and precancerous lesions of the upper and lower digestive tract in order to evaluate the efficacy and safety outcomes and to compare different resection techniques. In particular, the resection techniques investigated will be mucosectomy, en bloc and piecemeal, endoscopic submucosal dissection (ESD) and its variants, full-thickness resection. The anatomical districts involved will be the esophagus, stomach, duodenum, colon and rectum.


Eligibility criteria: Inclusion Criteria:

* 18 years or older
* all patients who have undergone endoscopic resection of an upper or lower digestive tract tumor

Exclusion Criteria:

* age under 18
* inability to provide informed consent

Primary outcomes:
measure: en bloc resection rate
timeFrame: one month
measure: complete resection rate
timeFrame: one month
measure: recurrence rate
timeFrame: one year
Secondary outcomes:
measure: adverse events rate
timeFrame: one month
measure: costs
timeFrame: one month
Other outcomes:
Locations:
city: Reggio Emilia
country: Italy
facility: IRCCS-AUSL Reggio Emilia
state: RE
Study officials:
References:
Clinical trial NCT05692856: Muscle Memory After Treatment With Anabolic Substance Clenbuterol and Resistance Training in Humans
Official title: Muscle Memory After Treatment With Anabolic Substance Clenbuterol and Resistance Training in Humans: Myonuclear Addition, Hypertrophy and Myocellular Reprogramming
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Skeletal Muscle Physiology
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
First posted: 2023-01-20
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of the project is investigate muscle memory and underlying mechanisms in humans following resistance training and use of the anabolic substance clenbuterol.


Eligibility criteria: Inclusion Criteria:

* Healthy men and women
* BMI of \<26 and normal ECG and blood pressure

Exclusion Criteria:

* Smoking
* Chronic disease,
* Use of prescription medication
* Pain due to current or previous musculoskeletal injury
* Resistance training more than once per week in the 12 months leading up to the intervention
* Current or previous use of prohibited anabolic substances

Primary outcomes:
measure: Fiber cross-sectional area
timeFrame: The change in fiber cross-sectional is assessed at baseline, 8, 24 and 32 weeks
measure: Myonuclei
timeFrame: The change in myonuclei is assessed at baseline, 8, 24 and 32 weeks
measure: Skeletal muscle proteome
timeFrame: The change in the muscle proteome is assessed at baseline, 8, 24 and 32 weeks
Secondary outcomes:
measure: Lean mass
timeFrame: The change in lean mass is assessed at baseline, 8, 24 and 32 weeks
measure: Isometric muscle strength
timeFrame: The change in maximal voluntary isometric contraction is assessed at baseline, 8, 24 and 32 weeks
measure: Dynamic muscle strength
timeFrame: The change in 1-repetition maximum is assessed at baseline, 8, 24 and 32 weeks
measure: Sprint performance
timeFrame: The change in sprint performance is assessed at baseline, 8, 24 and 32 weeks
measure: Satellite cells
timeFrame: The change in satellite cells is assessed at baseline, 8, 24 and 32 weeks
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: August Krogh Building
Study officials:
References:
Clinical trial NCT04405856: Outcome of Patients Treated With IABP
Official title: Outcome of Patients Treated With Intra Aortic Balloon Pump
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Acute Coronary Syndrome
Cardiogenic Shock
Coronary Artery Disease
Heart Failure
Left Ventricular Dysfunction
Low Cardiac Output Syndrome
Post-cardiac Surgery
Lead sponsor: Nanjing Medical University
Sponsor class: OTHER
First posted: 2020-05-28
Enrollment: 1000
Sex: ALL
Minimum age (years): 1
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients receiving IABP for circulatory support

Brief summary: Intra-Aortic Balloon Pumps (IABP) is a widely used and effective left ventricular adjuvant therapy. IABP is an inflatable device placed in the aorta that inflates with diastole and deflates with systole. The aim of this study is to investigate the outcome of patients treated With IABP, and to evaluate the short-term and long-term outcomes of patients with IABP.


Eligibility criteria: Inclusion Criteria:

* Patients receiving IABP for circulatory support

Exclusion Criteria:

* Refusal of consent

Primary outcomes:
measure: All-cause mortality
timeFrame: 30 days after IABP implantation
Secondary outcomes:
measure: All-cause mortality
timeFrame: 3 months after IABP implantation
Other outcomes:
Locations:
city: Nanjing
country: China
facility: The first affiliated hospital of nanjing medical university
state: Jiangsu
Study officials:
affiliation: The First Affiliated Hospital with Nanjing Medical University
name: Yong-feng Shao, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05726656: Effect of Wii-console Based Exercise on Shoulder Range of Motion for Post-mastectomy Lymphedema Patients
Official title: Effect of Wii-console Based Exercise on Shoulder Range of Motion for Post-mastectomy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Postmastectomy Lymphedema
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-02-14
Enrollment: 40
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: PURPOSE: To determine the effect of wii-console based exercise on shoulder ROM of both sides for post-mastectomy patients, and highlighting the effect of dominancy.

Detailed description: Breast cancer has been the focused of many studies because it significantly affects both in developed and developing countries worldwide (Cameirão et al, 2008).

Lymphedema affects the range of motion of shoulder causing disability and affection of function.

Wii-console systems can be used as training tools to promote intensive training directed towards specific deficits and guide the patients in task-oriented activities. Moreover, it allows a real-time high-resolution monitoring, where is possible to have a quantitative assessment of relevant properties of the impairment, performance and recovery. On the other hand, virtual reality environment demand focus and attention of the patient, motivate the patient to perform the exercises, and provide a sense of achievement to the user (Torre et al, 2015).

HYPOTHESES:

The wii-console based exercise will have no effect on shoulder ROM for post-mastectomy patients.

Eligibility criteria: Inclusion Criteria:

* All the patients will be females.
* Patients undergone mastectomy with lymph nodes dissection.
* all developed lymphedema after the surgery.

Exclusion Criteria:

* Vision problems.
* Medically instable patients.
* Balance disorders.
* Other musculoskeletal condition of shoulders.

Primary outcomes:
measure: shoulder range of motion
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Faculty of Physical Therapy
Study officials:
affiliation: Cairo University
name: Doaa A Atef, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06293456: Study of Poetic Dignity Therapy for Sexual and Gender Minority Patients With Cancer
Official title: An Open Trial of a Novel Poetic Dignity Therapy Intervention to Enhance Meaning and Purpose for Sexual and Gender Minority Patients With Cancer
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: End of Life
Keywords: Dignity Therapy (DT)
End of Life (EOL)
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2024-03-05
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to find out if dignity therapy is practical and works well for sexual and gender minority (SGM) patients in MSK. SGM includes, but is not limited to, people who identify as lesbian, gay, bisexual, transgender, and/or queer/questioning (LGBTQ+). Dignity therapy is a type of psychotherapy where the clinician asks the patient questions to allow the patient to express their individual life story and ultimately be able to create a legacy document of their experiences that can be shared with their loved ones.


Eligibility criteria: Inclusion Criteria:

* SGM (as per self-report) palliative care patients identified through Memorial Sloan Kettering Cancer Center's Palliative Care team and primary solid tumor oncology clinics.
* Age 18 and older (as per self-report/EHR)
* English-speaking as per the English language assessment items below and wil ing to receive the intervention in English.

  o What is the participant's preferred language?
* (Specify Lang)___________________________

  * How well does the participant speak English?
  * Very well (PARTICIPANT IS ELIGIBLE)
  * Well (PARTICIPANT is ELIGIBLE)
  * Not well (PARTICIPANT is NOT ELIGIBLE)
  * Not at all (PARTICIPANT is NOT ELIGIBLE)

Exclusion Criteria:

* Delirium/ altered mental status prohibitive of providing consent.

Primary outcomes:
measure: the number of patients who complete the intervention
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Basking Ridge
country: United States
facility: Memorial Sloan Kettering Basking Ridge (Consent only)
state: New Jersey
city: Middletown
country: United States
facility: Memorial Sloan Kettering Monmouth (Consent Only)
state: New Jersey
city: Montvale
country: United States
facility: Memorial Sloan Kettering Bergen (Consent Only)
state: New Jersey
city: Commack
country: United States
facility: Memorial Sloan Kettering Suffolk- Commack (Consent Only)
state: New York
city: Harrison
country: United States
facility: Memorial Sloan Kettering Westchester (Consent only)
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Uniondale
country: United States
facility: Memorial Sloan Kettering Nassau (Consent Only)
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: William E Rosa, Ph.D., MBE, NP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00743756: Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With Type 2 Diabetes Mellitus (DM)
Official title: Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With T2Dm
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Obesity
Diabetes
Keywords: obesity
diabetes
endothelial function
insulin sensitivity
Lead sponsor: Emory University
Sponsor class: OTHER
First posted: 2008-08-29
Enrollment: 38
Sex: ALL
Minimum age (years): 65
Maximum age (years): 85
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to assess the impact of home-delivered Medical Nutrition Therapy on clinical outcomes for persons with diabetes. The primary outcomes of this studies include A1c (A1C), blood glucose, blood pressure, Body Mass Index, lipid levels and other measures of disease progression and management as well as costs of medical care provided throughout the intervention period.

Detailed description: Data collected as a result of this project will be evaluated in aggregate to demonstrate the potential impacts on health and medical costs available through this type of intervention, with long-term goals of reducing disability and deaths due to chronic disease.

Eligibility criteria: Inclusion Criteria:

1. African-American subjects
2. Males or females 65 - 85 years of age
3. Body mass index (BMI) equal to or greater than 30 kg/m2
4. Fasting blood glucose less than 300 mg/dL and HbA1c less than 9.0%
5. Ability to understand and be willing to adhere to the study protocol
6. A known history of type 2 diabetes mellitus greater than 3 months, receiving either diet alone or oral antidiabetic agents (sulfonylureas, metformin, thiazolidinediones).

Exclusion Criteria:

1. Subjects with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state.
2. Patients with clinically relevant hepatic disease or impaired renal function, as shown by a serum creatinine greater than 3.0 mg/dL.
3. Mental condition rendering the subject unable to understand the scope of the study.

Primary outcomes:
measure: Weight Loss in the elderly african american population
timeFrame: 6 months to 1 year
Secondary outcomes:
measure: Endothelial Function (assessed by pulse-wave analysis); sympathetic activity; insulin sensitivity
timeFrame: 6 months to 1 year
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Grady Health System
state: Georgia
Study officials:
affiliation: Emory University
name: Guillermo E Umpierrez, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01814956: Different Lipid Emulsions in Acute Lung Injury Patients
Official title: Prospective, Randomized, Controlled, Double-blind, Parallel-group, Mono-center, Explorative Phase IV Trial on the Efficacy and Safety of a Fish Oil Containing Lipid Emulsion Versus a Standard Soybean-oil Based Lipid Emulsion in Patients With Acute Lung Injury
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Parenteral Nutrition
Lead sponsor: B. Braun Melsungen AG
Sponsor class: INDUSTRY
First posted: 2013-03-20
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Aim is to investigate the influence of an early supply of parenteral nutrition including a fish oil containing lipid emulsion on the course of acute lung injury in the intensive care unit. In comparison, a standard parenteral nutrition with a soybean oil based emulsion will be used. Data obtained in this trial may provide evidence for a beneficial effect of fish oil derived omega-3 fatty acids in parenteral nutrition regarding their influence on acute lung injury.


Eligibility criteria: Inclusion:

* Acute Lung Injury as a result of proven pneumonia (x-ray) or witnessed aspiration
* Oxygenation factor ≤ 300
* \<= 72 hours since intubation or non-invasive ventilatory support by mask at screening
* Expected need for parenteral nutrition for at least 5 days
* Male or female ≥ 18 years of age

Exclusion:

* Exclusion of pregnancy in women with child-bearing potential
* Cardiogenic pulmonary oedema
* Previous (\< 1 month) or ongoing need for corticosteroids \>0.1 mg/kg/d prednisolon-equivalent or other immune suppressive treatment
* Active or previous (\< 1 year) treatment for solid or haematologic malignancy
* Serum triglycerides \> 300 mg/dl at screening
* Alterations of coagulation (thrombocytes \<100 Giga/l), aPTT \> 60 sec, INR ≥ 2.5 without therapeutic intervention
* Autoimmune disease or HIV (according to medical history)
* Known or suspected drug abuse
* General contraindications to infusion therapy :

Primary outcomes:
measure: change in blood oxygenation (PaO2/FiO2ratio)
timeFrame: change day 1 to day 6
Secondary outcomes:
measure: Triglycerides
timeFrame: day 1 to day 16
measure: Sequential Organ Failure Assessment
timeFrame: day 1 to day 28
Other outcomes:
Locations:
city: Giessen
country: Germany
facility: University Clinic Giessen
Study officials:
References:
Clinical trial NCT02320656: Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015
Official title: Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Leukemia
Myelodysplastic Syndromes
Myeloproliferative Disorders
Lead sponsor: Institut Paoli-Calmettes
Sponsor class: OTHER
First posted: 2014-12-19
Enrollment: 650
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: HEMATO-BIO-IPC-2013-015 is a monocenter prospective longitudinal study. Our aim is to define predictive clinical and biological factors in acute leukemia, myelodysplastic syndromes and myeloproliferative disorders by using genomics, genetics and epigenetics, in vitro and in vivo drug sensitivity studies,and translational immonulogy and immunomonitoring studies.

HEMATO-BIO primary outcome measure is to identify molecular, genomic and epigenetic, pharmacologic and immunophenotypic alteration in acute leukemia, myelodysplastic syndromes and myeloproliferative disorders by collecting, at diagnosis and/or complete remission and/or relapse:

* tumor samples: marrow aspiration, blood sampling.
* non-tumor samples: skin biopsy, buccal swab . from 650 patients treated at our cancer center.


Eligibility criteria: Inclusion Criteria:

* acute leukemia, myelodysplastic syndrome or myeloproliferative disease
* age \> 18
* affiliated to the French Social Security Systm
* signed informed consent

Exclusion Criteria:

* emergency
* patients deprived of liberty or placed under the authority of a tutor

Primary outcomes:
measure: Acute leukemia/ Myeloproliferative/ myelodysplastic syndrome cells profiling (molecular analysis, epigenetic profile, drug sensitivity profile,immunophenotyping)
timeFrame: up to 8 years
Secondary outcomes:
measure: Correlation between molecular alteration and clinical characteristics(diagnosis,cytogenetics,overall survival, progression free survival)
timeFrame: up to 8 years
measure: Compare cancer and non-tumor cells genome
timeFrame: up to 8 years
Other outcomes:
Locations:
city: Marseille
country: France
facility: Institut Paoli-Calmettes
Study officials:
affiliation: Institut Paoli-Calmettes
name: Norbert Vey, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chretien AS, Devillier R, Granjeaud S, Cordier C, Demerle C, Salem N, Wlosik J, Orlanducci F, Gorvel L, Fattori S, Hospital MA, Pakradouni J, Gregori E, Paul M, Rochigneux P, Pagliardini T, Morey M, Fauriat C, Dulphy N, Toubert A, Luche H, Malissen M, Blaise D, Nunes JA, Vey N, Olive D. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. Proc Natl Acad Sci U S A. 2021 Jun 1;118(22):e2020459118. doi: 10.1073/pnas.2020459118.
Clinical trial NCT00966056: Study of Mitomycin C and Nasal Splint to Treat Nasal Synechiae
Official title: Comparative Study of Mitomycin C and Internal Nasal Septal Splint in the Treatment of Nasal Synechiae
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Nasal Synechiae
Adhesions of Nasal Cavity
Nasal Adhesions
Tissue Adhesions
Keywords: Nasal adhesions
Nasal synechiae
Mitomycin
Mitomycin c
Teflon
Splints
Septal splints
Lead sponsor: Karnataka Institute of Medical Sciences
Sponsor class: OTHER
First posted: 2009-08-26
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates whether Mitomycin C is an effective alternative to septal splints in the treatment of nasal synechiae.

Detailed description: Nasal synechiae is an important cause for the failure of many a nasal surgery. Septal splints have been widely used for the treatment of nasal synechiae, but are associated significant morbidity until removal. To the best of our knowledge there are no studies in literature comparing Mitomycin C with septal splints as an atraumatic alternative in the treatment of nasal synechiae. This is a preliminary study taken up to evaluate the therapeutic efficacy of Mitomycin C in the treatment of nasal synechiae.

Eligibility criteria: Inclusion Criteria:

* Patients with nasal mucosal synechiae due to surgical or non-surgical trauma

Exclusion Criteria:

* Patients with nasal vestibular stenosis
* Patients with nasal synechiae due to diseases like Hansen's disease, Syphilis, Rhinoscleroma, Atrophic Rhinitis etc.

Primary outcomes:
measure: Recurrence or absence of synechiae
timeFrame: 1 week, 1 month, 2 months
Secondary outcomes:
measure: Symptoms and complications
timeFrame: 1 week, 1 month, 2 months
Other outcomes:
Locations:
city: Hubli
country: India
facility: Karnataka Institute of Medical Sciences
state: Karnataka
Study officials:
affiliation: Karnataka Institute of Medical Sciences
name: VIKRAM K BHAT, MS(ENT), DNB
role: STUDY_CHAIR
References: